QiangNao Technology raises 2 billion in funding, setting a record: the industrial turning point of brain-computer interfaces from concept to mass production

Brain-Computer Interface (BCI) field welcomes a major financing event. On January 6, Hangzhou QiangNao Technology announced the completion of approximately 2 billion yuan in funding, setting the second-largest financing record in the global BCI track, second only to Neuralink under Elon Musk. This round of financing not only reflects capital’s confidence in this field but also highlights the complete industrial chain layout behind it—from investors to manufacturers to application scenarios—the entire ecosystem has already formed. This marks the official transition of non-invasive brain-computer interface technology from R&D to a period of commercial explosive growth.

Record-breaking Financing Scale, Luxurious Industry Chain Lineup

The investor lineup for this round of financing is considered luxurious, covering three levels: financial capital, industrial capital, and strategic capital:

The most noteworthy role is played by Lens Technology. As a leader in the “fruit chain,” Lens Technology not only makes strategic investments but also exclusively undertakes mass production of core hardware modules for QiangNao Technology. What does this mean? The biggest bottleneck for products moving from the lab to the market—manufacturing capacity—has been solved. This deep integration of “capital + manufacturing” solidifies the supply chain foundation for large-scale deployment.

Technological Accumulation and Commercialization Progress

QiangNao Technology was founded in 2015 and is one of the “Hangzhou Six Little Dragons,” focusing on non-invasive brain-computer interface technology R&D. Simply put, it achieves brain-machine interaction without craniotomy or electrode implantation, by collecting EEG signals from the scalp surface.

The company’s technical strength is reflected in several data points:

• Over 70% of the core R&D team members are alumni from top universities like Harvard and MIT
• Nearly 200 core invention patents have been obtained
• Achieved the world’s first high-precision brain-computer interface product with a mass production of 100,000 units
• Its BrainCo intelligent bionic hand achieves 0.1mm sub-millimeter operation accuracy and a 99% signal recognition rate

What do these data indicate? Technology is no longer a bottleneck; products can be mass-produced, and usability has been validated. This is not just PPT-style fundraising but based on solid technological accumulation and product validation.

Use of Funds and Commercial Goals

According to official statements, the 2 billion yuan in funding will be used for four directions:

• Fully accelerate core BCI technology R&D
• Breakthroughs in extreme engineering (referring to product reliability, durability, and other engineering issues)
• Scale-up of products (from small batches to large-scale production)
• Mass deployment (from lab to market)

The corresponding commercial goals are also clear—within five to ten years:

• Help 1 million people with disabilities regain daily life through neural-controlled prosthetics
• Improve the condition of 10 million patients suffering from autism, ADHD, Alzheimer’s, insomnia, and other brain diseases
• Enable ordinary people to interact with the world through brain-machine interfaces using only their thoughts

These three goals span medical applications, brain disease treatment, and consumer experience, demonstrating that QiangNao Technology’s ambitions go beyond healthcare to build a complete brain-computer interface ecosystem.

Market Response and Industry Opportunities

After the financing news was announced, the A-share BCI sector “took off” directly. On January 5, the BCI concept index surged over 13% intraday, with multiple stocks hitting the daily limit. This reflects the market’s enthusiasm for this track.

From the industry chain perspective, QiangNao Technology’s upstream involves chips, sensors, materials, etc., downstream involves medical devices, consumer electronics, and the midstream core BCI technology. This financing event will have a demonstration effect on the entire industry chain—proving that this path can be successful, and capital will continue to follow.

Future Outlook

Summary

QiangNao Technology’s 2 billion yuan financing essentially sends a signal: non-invasive brain-computer interfaces have evolved from a “tech concept” to an “industrialization stage.” It has complete technology, sufficient funding, mature industry chain partners, and clear commercial goals. This is not a short-term capital craze but the beginning of a long-term industry. Over the next five to ten years, whether brain-computer interfaces can truly change the lives of disabled people and improve the condition of brain disease patients remains to be seen.